Contribution: Industrial Research Assistance Program – Contributions to Firms
Vasomune Therapeutics Inc.
$2,849,345.00
COVID-19 Phase 1 SAD/MAD FIH Clinical Trial of AV-001
EF 2020-21 · 2020-11-01
Résumé
Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with severe COVID-19 disease. The phase 1 study is the first-in-human study designed to demonstrated safety and tolerability of AV-001 in heathy subjects prior to testing in severely ill patients with COVID-19 disease.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Toronto|Toronto, Ontario, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
833657133
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 0 | 2020-11-01 | 2020-21 | $1,260,000.00 |
| 1 | 2020-11-01 | 2020-21 | $2,849,345.00 |
| 2 | 2020-11-01 | 2020-21 | $2,849,345.00 |
| 3 | 2020-11-01 | 2020-21 | $2,849,345.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 334 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 334 jours.
Agreement End Date
2023-02-28
Agreement Number
965762
Agreement Start Date
2020-11-01
Agreement Title
COVID-19 Phase 1 SAD/MAD FIH Clinical Trial of AV-001
Agreement Title (French)
COVID-19 Phase 1 SAD/MAD FIH Essai clinique de l'AV-001
Agreement Type
Contribution
Agreement Value
$2,849,345.00
Amendment Date
2022-04-08
Amendment Number
3
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Vasomune is developing a novel first-in-class investigational medicine to treat patients hospitalized with severe COVID-19 disease. The phase 1 study is the first-in-human study designed to demonstrated safety and tolerability of AV-001 in heathy subjects prior to testing in severely ill patients with COVID-19 disease.
Description (French)
Vasomune conçoit un nouveau médicament expérimental, le premier de sa catégorie, pour traiter les patients hospitalisés pour la COVID-19 gravement malade. L'étude de la phase 1 est la première étude chez l'homme conçue pour démontrer la sécurité et la tolérabilité de l'AV-001 chez des sujets en santé avant de le tester chez des patients gravement malades atteints de la COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Spadina--Fort York
Federal Riding (French)
Spadina--Fort York
Federal Riding Number
35101
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
833657133
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Vasomune Therapeutics Inc.
Recipient Postal Code
M5T 1X5
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2020-2021-Q4-965762
